Site
Search results
U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA®) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy
Apr 04, 2017 United States GVHD is a life-threatening condition with limited treatment options Milestone highlights the potential benefit of ibrutinib beyond blood cancers RARITAN, NJ, April 4, 2017 – Janssen Research & Development, LLC announced ...
Late-breaking Phase 2 Ibrutinib Study in Chronic Graft-Versus-Host-Disease (cGVHD) Showed Complete or Partial Response in Up to Two-Thirds of Steroid Dependent or Refractory Patients
Dec 06, 2016 United States Data at the American Society of Hematology Annual Meeting highlight potential role of ibrutinib therapy beyond hematologic cancers cGVHD is a major cause of stem cell or bone marrow transplant-related illness, death and ...
U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy
Aug 02, 2017 United States The approval provides an important new treatment option for adults living with debilitating and potentially life-threatening condition This is the first indication for IMBRUVICA outside of oncology and its sixth U.S. indication ...